Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Meta's aggressive open-source strategy for large models is a wedge into developer mindshare and ad inventory optimization. The move risks commoditizing models but also strengthens Meta's platform control and potential monetization across the Family of Apps. We like a mid-term long: entry $599.21, target $720.00, stop $540.00 — horizon 45 trading da…
Global disruptions that keep Russian refined exports effectively sidelined create a multi-month tailwind for U.S. refiners. Marathon Petroleum (MPC) sits at the center of that upside: large scale, integrated refining plus midstream optionality, strong free cash flow, and an attractive valuation on trailing earnings. This trade idea outlines a mid-t…
Merchants Bancorp (MBIN) reported a record asset base in Q2 2026 and continues to draw large institutional interest. With a market cap near $2.5B, a P/B around 1.07 and a 2.4% dividend yield, MBIN looks like a reasonable long candidate for investors willing to weather legal noise and funding-cost volatility. This trade idea lays out an entry at $54…
Ciena is benefitting from hyperscaler optical upgrades tied to the AI infrastructure buildout. Strong top-line momentum, a sizable backlog and robust free cash flow support further upside, but stretched multiples and recent capital markets activity introduce near-term risk. This trade idea frames a mid-term swing entry with explicit entry, target a…
Cheniere just cleared another operational milestone and lifted its forward posture on growth. With Train 6 at Corpus Christi now substantially complete and incremental capacity coming online, the stock trades below its 52-week high and at valuation multiples that the market can reconcile with steady cash flow. This trade idea lays out an entry, sto…
Gilat Satellite Networks offers diversified exposure to the expanding satellite communications market via fixed networks, mobility terminals, and an upcoming strategic acquisition. The stock is actionable from current levels, but the trade depends on execution of Comtech integration, sustained defense orders, and order flow from multi-orbit constel…
Cineverse (CNVS) is a micro-cap streaming and media-technology operator trading at roughly $2.77 with a market cap near $73M. The stock discounts its Matchpoint technology and recently aggregated FAST and SVoD assets. We see asymmetric upside if execution on ad tech and FAST monetization accelerates; trade plan: enter at $2.70, target $5.50, stop $…
Cheniere Energy has just cleared another milestone at Corpus Christi and is entering a multi-year capacity expansion cycle at a time when global LNG supply is under pressure. Fundamentals - contracted cash flows, solid free cash flow generation and visible capacity adds - make a long trade attractive over a 180-trading-day horizon with asymmetric u…
Southern Company ($SO) looks attractively positioned after a steady quarter, a supportive federal nuclear program, and a yield north of 3%. We upgrade to a buy and lay out an actionable trade with entry at $91.00, stop at $86.00, and a target of $100.84 over the next 180 trading days.
Seaport Therapeutics (SPTX) is a clinical-stage neuropsychiatry company trading at roughly $1.4B market cap with a tight float, high short interest and bullish technical momentum. The stock offers development-arbitrage upside if clinical/program milestones or partnership chatter re-rate the valuation; the trade is actionable with a mid-term horizon…
Marvell's sell-off has carved out a tactical buying opportunity. Strong AI-driven demand, healthy free cash flow and a clean balance sheet argue for a mid-term long. This trade plan gives a clear entry ($205.00), stop ($195.00) and target ($260.00) with a 45-trading-day horizon to let AI revenue momentum and technical mean reversion work in your fa…
Pfizer is an income-oriented pharma with a deep late-stage pipeline in obesity and oncology. The stock yields near 6.9%, trades around $26.60 and offers an asymmetric reward if late-stage assets like berobenatide and oncology candidates succeed. We lay out an actionable long trade with entry, stop and target and explain the catalysts, valuation con…
Repsol’s ADR is an actionable long with a clear entry, stop and target. European refining capacity remains tight, supporting margins for companies with integrated refineries. At the same time, Repsol’s push into renewable fuels (notably the Ecoplanta waste-to-methanol contract) gives the stock optionality in the energy transition. Technicals show a…
Wendy's recent management change and a trimmed payout create the cash-flow and governance backdrop for a turnaround. At roughly $1.44B market cap and trading near $7.55, the stock is attractively valued on traditional metrics; this trade targets a mid-term rerating as execution and catalysts play out.
Extreme Networks is trading well below its recent highs after a margin-driven pullback. The selloff discounts a platform transition toward cloud-native, software-defined networking and AI-enabled management. With $105M of free cash flow, a $3.12B market cap and double-digit revenue growth last year, this is a tactical long for investors willing to …
Ferrari trades at a premium, but recent Q2 strength, a raised 2026 guide, aggressive buybacks and the most complete product lineup in decades justify owning the stock. This trade idea lays out an actionable long with entry, stop and target for a long-term holding (180 trading days), explains the fundamental drivers and balances the bull case with c…
Lyft is not the global behemoth Uber is, but it has carved an economically viable niche in North America. With free cash flow of roughly $1.12B, a market cap near $7.0B and a P/E around 2.3, Lyft looks attractively priced for a mid-term tactical long. Trade plan: enter $17.55, stop $15.00, target $22.00 over a mid term (45 trading days).
Kodiak Gas Services (KGS) combines fixed-revenue contract compression with expanding distributed power opportunities tied to AI and edge power demand. The company trades at about $61.05 with a $6.54B market cap, EV/EBITDA of ~12.9 and annual free cash flow of roughly $200M. We outline a long trade with clear entry, stop and target, plus the catalys…
Meta Platforms ($META) looks oversold relative to its fundamentals. The company generates roughly $41B in free cash flow, sports a 26% return on equity, and trades at ~22x earnings - not nosebleed for a company executing AI and ad monetization plays. This trade targets a mean-reversion and sentiment rebound into AI spending updates and ad cadence o…
Guardant Health is the leading pure-play liquid biopsy name. Recent FDA expansion for Guardant360 Liquid CDx, strong technicals, and large market projections for cancer biomarkers create a clear growth narrative. This trade idea outlines a long position with precise entry, stop and target, while laying out catalysts, valuation context and risks tie…
Nvidia's latest large acquisition meaningfully expands its addressable AI stack and strengthens its moat in data-center AI. We upgrade to a constructive rating and offer a long trade designed to capture post-deal integration upside while managing valuation risk.
UnitedHealth's post-2025 profit recovery looks sustainable as medical care ratios normalize and Optum tailwinds resume. The company trades below prior highs with solid free cash flow and dividend support. This trade idea lays out an entry at $405.00, a $460.00 target and an $388.00 stop for a long-term trade (180 trading days).
Rackspace is generating positive free cash flow today and trades at an attractive price-to-sales multiple. The stock has been punished this year on restructuring and disclosure noise, but the base business - particularly Private Cloud margins and a capital-light Public Cloud services model - still turns cash. If the company can monetize enterprise …
Intuitive Machines (LUNR) is trading near $16.28 after a string of favorable NASA awards and a $1.1 billion backlog. The company remains unprofitable but has record quarterly revenue and an attractive risk-reward for a tactical long with a 180 trading day horizon. This trade plan lays out entry at $16.20, stop at $13.50 and a $25 target tied to con…
BridgeBio (BBIO) just delivered more than clinical validation with Attruby's meaningful mortality benefit and continues to de-risk multiple near-term commercial events. With a strengthened balance sheet from a $1B preferred equity raise and positive Phase 3 data for BBP-418, the risk/reward tilts toward a long trade over the next 180 trading days. …
